SARM1: A Potential Therapeutic Target for Neurodegenerative Diseases

Neurological disorders are considered the second leading cause of death and the primary cause of long-term disability, worldwide.

In fact, over 6.5 million neurological disorder related deaths are reported annually, globally. Further, according to a report published by the United Nation (UN), close to 1 billion people, across the globe, suffer from various types of neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and multiple sclerosis. The growing number of patients suffering from neurodegenerative disorders has imposed a huge burden, in terms of finances as well as resources, on the overall healthcare system. In this context, it is worth mentioning that the annual expenditure associated with neurological disorder care in 2020 was more than USD 655 billion, in the US alone. SARM1 inhibitors have the potential to overcome these challenges and address the unmet need.

For additional details, please visit https://www.rootsanalysis.com/blog/sarm1/